89bio Will Present 48-Week Data From ENLIVEN Phase 2b Pegozafermin Trial In MASH At EASL International Liver Congress
Portfolio Pulse from Benzinga Newsdesk
89bio, Inc. (NASDAQ:ETNB) will present 48-week data from its Phase 2b ENLIVEN trial evaluating pegozafermin in patients with MASH at the EASL International Liver Congress in June 2024.
May 22, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
89bio, Inc. (NASDAQ:ETNB) will present 48-week data from its Phase 2b ENLIVEN trial evaluating pegozafermin in patients with MASH at the EASL International Liver Congress in June 2024. This could generate significant interest and potentially impact the stock price positively.
The presentation of 48-week data from a Phase 2b trial at a major international congress is a significant milestone for a clinical-stage biopharmaceutical company. Positive data could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100